ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
National Resilience, a biopharmaceutical development and manufacturing firm, has entered an agreement with Lifera, owned by a private investment fund, to develop biopharmaceutical production in Riyadh, Saudi Arabia. Resilience, which debuted in 2020, will undertake the design, construction, and commissioning of a plant that meets the quality standard of the US Food and Drug Administration’s current good manufacturing practices. Resilience will have a minority ownership stake in the plant, which will produce sterile injectables and other parenteral products to meet local and regional demand.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter